The Timing Window the Lugano Classification Sets
Most lymphoma cases in active oncology clinics are diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma. Both types need imaging during treatment to check how well the patient is responding before all cycles finish. The Lugano classification sets the standard for lymphoma staging and response assessment. It uses FDG-PET/CT as the main imaging tool for lymphomas that show up on PET scans. For Hodgkin lymphoma and DLBCL, doctors order an interim PET after cycle 2, called iPET2. Some treatment plans also call for another PET scan after cycle 4.
The scan window is narrow. Nuclear medicine departments schedule these scans 14 to 17 days after the last drug dose of the previous cycle. This timing is close enough to the cycle end to show how the cancer is responding, but far enough from the drug's immediate effects to avoid confusion. End-of-treatment scans happen 6 to 8 weeks after the final cycle. If you miss the interim window by much in either direction, the scan may not answer the clinical question it was supposed to address.
Research published in the journal Cancers shows that an interim PET scan after two cycles is a strong predictor of whether DLBCL patients will respond to treatment. If the interim scan is clear, the clinical team gets important information before cycles 5 or 6 are given. This predictive value only holds if you scan at the right point in the cycle sequence. Outside the protocol window, the scan loses its power to predict the outcome.
Where Clinic Operations Miss the Window
The staging calendar does not run itself. Booking an interim PET in most oncology clinics needs at least three departments: oncology to confirm cycle 2 is complete and the patient is stable; nuclear medicine or radiology to book the scan and prepare the radiopharmaceutical; and scheduling to place the appointment in the narrow date range tied to the cycle. Add payer prior authorization and the window gets even tighter.
Several breakdowns commonly disrupt this chain:
- Cycle delays from toxicity or lab results. Low neutrophil counts can delay cycle 2 by days or a week. Most scheduling systems do not connect to cycle-specific treatment data. When cycle 2 finally completes, nothing automatically adjusts the PET date to match the new timeline. Someone has to notice and change it manually.
- Referral handoff gaps between oncology and radiology. An interim PET referral can sit in a radiology queue while the patient moves through cycle 3. By the time the scan is booked, it may not answer the original clinical question anymore.
- Calendar tools that do not track treatment cycles. Standard appointment calendars work on fixed dates. They do not know that an appointment is tied to a cycle count. When the cycle shifts, the appointment does not shift with it. No alert warns anyone about this mismatch until someone notices.
- Communication barriers across departments. Research on multiple sites found that chemotherapy delays came from problems in how departments were organized, how they communicated, and what communication tools they used. Lymphoma re-staging has the same problems when oncology and imaging services hand off patients.
An ASCO educational resource recommends booking the interim PET at the start of treatment to prevent scheduling drift during treatment. This guidance shows how fragile the process is when departments coordinate by hand and do not share a real-time view of the treatment timeline.
What Slippage Costs the Clinic
Missed interim PET windows have compounding effects. The oncologist must decide whether to give the next cycle based only on older imaging or clinical judgment. Postponing the scan delays the cycle start. Ordering an out-of-window scan creates documentation risk when payers check whether the imaging date matches the treatment protocol.
There is also a money side to this. Properly timed and documented staging scans help with billing for the evaluation and management visit. Missing documentation or out-of-order scan records lead to claim denials. In a six-cycle treatment with two staging scans, one missed or delayed scan can create extra work across multiple patient visits.
Protocol deviations also show up in quality reports. ASCO research found that gaps in care quality often come from poor coordination and failure to plan care, not from errors in clinical judgment. The scheduling layer is where many of these gaps start - and where they are hardest to spot in real time.
A Treatment Timeline Versus a Scheduling Calendar
The difference between a calendar and a treatment timeline may sound small. In clinical operations it decides whether the scheduling layer stays connected to the protocol or drifts away from it as treatment goes on.
A treatment timeline tracks that a patient is on R-CHOP cycle 2, day 17. It can show a notification visible to the oncologist, the scheduling team, and the nuclear medicine coordinator that an interim PET is due within a specific date range, and that the range moves if cycle 2 was delayed. A standard calendar only knows that an appointment exists on a given date. If the cycle moves, the calendar is wrong and no alert warns anyone.
Some systems attach surveillance checkpoints to treatment cycles rather than calendar dates. When a cycle date moves, linked checkpoints move with it, and the responsible staff member gets a notification before the imaging window closes. A treatment timeline approach ensures that scheduling stays tied to the actual treatment phase, not to fixed calendar dates.
The same idea works for end-of-treatment scans. Once the final cycle is marked complete, the system should prompt the team to book the 6-to-8-week post-treatment PET with the target date range and active authorization record in the same task. This saves the team from having to look up that information in a paper protocol or separate document system.
When radiology reports arrive - whether as structured HL7 messages or scanned PDFs - a good system should extract the Deauville score and key findings into the patient record. The oncologist reviews a structured summary at the next clinical visit instead of finding and reading a PDF in a separate viewer. Extracting key data from radiology reports saves time and reduces errors.
Where to Start for Active Lymphoma Protocols
Clinics running both Hodgkin and DLBCL protocols at the same time often have three or four active re-staging windows going on. Each involves a different patient, a different cycle count, and possibly a different payer authorization requirement. Manual tracking across oncology, scheduling, and nuclear medicine is where errors pile up - often with no single department knowing that a window has drifted.
The fix starts with seeing what is happening. Mapping active lymphoma patients by treatment cycle instead of just by date usually finds drifting re-staging windows within the first week. The next question is whether scheduling and imaging departments get automated alerts tied to cycle data or if they rely on a coordinator checking a separate list.
Clinics trying to find where surveillance slippage is worst across their patients should also look at how scheduling failures happen and what works across different cancer types. These operational patterns show up across many disease areas, not just lymphoma.
Cycle-anchored scheduling aligns the treatment timeline with the actual protocol. Book a demo to see how this works.